Dalidowicz, M. What is the magnitude of risk of exposure to coronaviruses with intermediate and high risk upper GI endoscopy, ERCP and colonoscopy? 2020 Mar 31; Document no.: EOC033101-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 9 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc8
Dalidowicz, M. Where and how are they producing and using intubation hoods? 2020 Mar 30; Document no.: EOC033001-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 6 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc9
Dalidowicz, M; Young, C. What is the degree of COVID-19 transmission through the administration of nebulizer medication either in clinical practice or in animal experiments? 2020 Apr 1; Document no.: EOC040101-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 12 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc10
Badea, A; Groot, G; Dalidowicz, M; Young, C; Miller, L. What is the prevalence of sore throat as a symptom of COVID-19? 2020 Apr 7; Document no.: EOC040201 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 8 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc15
Dalidowicz, M; Young, C; Miller, L. What is the prevalence of sore throat as a symptom of COVID-19? 2020 Apr 7; Document no.: EOC040201-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 16 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc19
McCarron, M; Groot, G; Dalidowicz, M; Miller, L. What distinguishes COVID-19 from influenza-like illnesses? 2020 Apr 17; Document no.: PPE041701 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc32
Miller, L; Dalidowicz, M. What distinguishes COVID-19 from influenza-like illnesses? 2020 Apr 16; Document no.: PPE041701-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 15 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc33
Miller, L; Dalidowicz, M. What is the clinical evidence used to support aerosol generating medical procedures recommendations and guidelines regarding line flow volume or pressure? 2020 Apr 11; Document no.: PPE041702-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 12 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc34
Young, C; Dalidowicz, M; Mueller, M. What is the period of communicability of symptomatic SARS-CoV-2? 2020 Apr 25; Document no.: INF042401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 35 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc56
Williams-Roberts, H; Lee, S; Young, C; Dalidowicz, M; Mueller, M. What is the period of communicability of symptomatic SARS CoV-2? 2020 Apr 27; Document no.: INF042401 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 24 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc57
